Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) Target Price at $50.08

Shares of Pharvaris N.V. (NASDAQ:PHVS) have been given an average rating of “Moderate Buy” by the fourteen brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $50.0833.

A number of brokerages recently commented on PHVS. Citigroup restated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Royal Bank Of Canada dropped their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. UBS Group set a $74.00 target price on Pharvaris in a research note on Wednesday, May 13th. Citizens Jmp decreased their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. Finally, Wolfe Research started coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock.

Pharvaris Stock Performance

Shares of PHVS opened at $34.36 on Thursday. The stock has a market capitalization of $2.25 billion, a P/E ratio of -10.80 and a beta of -2.34. Pharvaris has a 1 year low of $19.12 and a 1 year high of $36.60. The company’s fifty day moving average is $32.33 and its two-hundred day moving average is $29.15.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.12. Sell-side analysts predict that Pharvaris will post -3.2 EPS for the current year.

Insider Buying and Selling

In other news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the transaction, the director owned 315,167 shares in the company, valued at $11,185,276.83. This trade represents a 8.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Viviane Monges sold 9,667 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.29, for a total transaction of $292,813.43. Following the completion of the sale, the director owned 5,500 shares of the company’s stock, valued at $166,595. This trade represents a 63.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 274,555 shares of company stock valued at $8,880,601 in the last quarter. Corporate insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PHVS. Geode Capital Management LLC lifted its position in shares of Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares during the period. JPMorgan Chase & Co. increased its stake in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc increased its stake in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi increased its stake in Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Pharvaris by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after purchasing an additional 7,879 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.